Compare · AXSM vs DFTX
AXSM vs DFTX
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while DFTX focuses on Medicinal Chemicals and Botanical Products.
- AXSM is the larger of the two at $6.80B, about 1.8x DFTX ($3.88B).
- DFTX has been more active in the news (9 items in the past 4 weeks vs 5 for AXSM).
- AXSM has more recent analyst coverage (25 ratings vs 8 for DFTX).
- Company
- Axsome Therapeutics Inc.
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $6.80B
- $3.88B
- 1M return
- -
- -21.27%
- 1Y return
- -
- +141.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 8
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest AXSM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
- Truist resumed coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Chief Operating Officer Jacobson Mark L. sold $2,086,500 worth of shares (10,000 units at $208.65) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $12.95 (SEC Form 4)
Latest DFTX
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026